RTP Mobile Logo
Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Gastrointestinal Cancer: A Clinical Investigator Think Tank
Released October 2012

Video excerpts from a Clinical Investigator Think Tank held on 7/13/2012. Featuring perspectives from Drs Tanios Bekaii-Saab, Emily K Bergsland, Charles S Fuchs, Richard M Goldberg, Axel Grothey, Matthew Kulke, Bert H O’Neil and Alan P Venook. (Video Program)

CE Disclosures and Faculty Information


    This activity is intended for medical oncologists and other healthcare providers involved in the treatment of gastrointestinal cancers.


    Because of the prevalent nature of the disease, extensive resources are allocated to colorectal cancer (CRC) research and education. Interestingly, however, although individually less frequently encountered, non-CRC gastrointestinal (GI) cancers collectively account for more per annum cancer-related deaths than do tumors of the colon and rectum combined. Published results from ongoing trials in both these fields continually lead to the emergence of novel biomarkers and new therapeutic targets and regimens, thereby altering existing management algorithms. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. This CME program uses a roundtable discussion with leading GI clinical investigators to assist practicing clinicians in formulating up-to-date and appropriate clinical management strategies.

    • Apply clinical research data to optimize the use of anti-VEGF-based therapy in the treatment of advanced CRC.
    • Appropriately integrate multigene assays when communicating prognosis and treatment options to patients with early-stage colon cancer.
    • Evaluate the use of locoregional interventions for patients with unresectable hepatocellular carcinoma.
    • Educate patients with neuroendocrine tumors of the GI tract about available systemic therapies and approaches to their optimal sequencing for unresectable metastatic disease.
    • Communicate the benefits and risks of existing and emerging tyrosine kinase inhibitors for the treatment of high-risk or metastatic gastrointestinal stromal tumors.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


    Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Tanios Bekaii-Saab, MD
    Section Chief, Gastrointestinal Oncology
    Chair, CCC Gastrointestinal Disease Research Group
    Associate Professor of Medicine and Pharmacology
    The Ohio State University – James Cancer Hospital
    Columbus, Ohio

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Onyx Pharmaceuticals Inc, Sanofi; Data and Safety Monitoring Board: Polaris Group; Paid Research: Pfizer Inc.

    Emily K Bergsland, MD
    Professor of Clinical Medicine
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company; Paid Research: Novartis Pharmaceuticals Corporation; Research Support: Genentech BioOncology, Sanofi.

    Charles S Fuchs, MD, MPH
    Director, Center for Gastrointestinal Cancer
    Dana-Farber/Harvard Cancer Center
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee
    : Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Pfizer Inc, Roche Laboratories Inc, Sanofi; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Pfizer Inc, Roche Laboratories Inc, Sanofi.

    Richard M Goldberg, MD
    Professor of Medicine
    Physician-in-Chief, OSUCCC – James Cancer Hospital and Richard J Solove Research Institute
    Klotz Family Chair in Cancer Research
    The Ohio State University
    Columbus, Ohio

    Advisory Committee:
    Bayer HealthCare Pharmaceuticals; Consulting Agreements: Genomic Health Inc, Sanofi; Data and Safety Monitoring Board: Lilly USA LLC.

    Axel Grothey, MD
    Professor of Oncology
    Department of Medical Oncology
    Mayo Clinic
    Rochester, Minnesota

    Paid Research
    : Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Genentech BioOncology.

    Matthew Kulke, MD, MMSc
    Director, Program in Neuroendocrine and Carcinoid Tumors
    Dana-Farber/Brigham and Women’s Cancer Center
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: Novartis Pharmaceuticals Corporation, Pfizer Inc.

    Bert H O’Neil, MD
    Associate Professor
    Director, GI Oncology Clinical Research Program
    Medical Director, UNC Cancer Clinical Trials Protocol Office
    UNC Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina

    Advisory Committee:
    Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Sanofi; Consulting Agreements: Abbott Laboratories, Genentech BioOncology; Data and Safety Monitoring Committee: GlaxoSmithKline; Speakers Bureau: Genomic Health Inc.

    Alan P Venook, MD
    Professor of Clinical Medicine
    University of California, San Francisco
    San Francisco, California

    Advisory Committee:
    Myriad Genetics Inc; Paid Research: Bayer HealthCare Pharmaceuticals, Genentech BioOncology, GlaxoSmithKline.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Prometheus Laboratories inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Foundation Medicine Inc, Genomic Health Inc, Lilly USA LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals and Sanofi.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date:
    October 2012
    Expiration date:
    October 2013

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):